(May 2017) In January 2016, Dean John Reilly, Jr., MD, announced five recipients of Transformational Research Funding awards.
awards are major investments in programs that will position the
University of Colorado School of Medicine as a leader in cutting-edge
and emerging fields, attract extramural funding, help recruit and retain
outstanding faculty, enhance education and training, and positively
impact human lives and society in Colorado, the nation and the world.
investments are funded by the Dean’s Office with a portion of clinical
earnings by the faculty, from annual financial support from UCHealth,
and from philanthropic contributions, including a commitment of $15
million by The Anschutz Foundation. No state-appropriated funding or
student tuition or fees are being used for the Transformational Research
The awards were selected with the assistance of a
committee of external reviewers who considered about 40 proposals
submitted by faculty teams.
The initiatives that were selected are expected to catalyze:
Innovative scholarship that makes significant contributions to
knowledge and science in areas of strategic importance to CU, and that
has potential to improve human lives, society, the environment, or the
economy, will enhance culture and community, or provide other public
• Multidisciplinary collaboration that positions CU as a national leader in these selected areas;
Faculty teamwork across career stages to provide mentorship, support
professional advancement, and position CU faculty as leaders in key
• Training opportunities in cutting-edge interdisciplinary or multi-disciplinary research.
Each project has a five-year budget totaling between $10 million and $20 million
the past year, the leaders of the initiatives have been recruiting
faculty, managing resources that promote collaborative science,
organizing training and educational programming and sponsoring pilot
Each project is profiled on the following pages of this issue of CU Medicine Today. The five projects are
Consortium for Fibrosis Research & Translation (CFReT) –
Investigators in this program are working to discover the mechanisms
that govern pathological fibrosis and to develop treatment for patients
with diverse fibrotic diseases.
• Data Science to Patient Value (D2V) – This initiative focuses on Big Data methods, their applications
to medicine and health care delivery, and ultimately, the achievement of
high value, patient-centered health care.
• GI and Liver Innate Immune Programs (GALIIP) – Researchers are addressing the unmet need in
diagnosis, treatment and understanding of many gastrointestinal and
liver diseases, including fatty liver disease, eosinophilic esophagitis
and inflammatory bowel disease.
• Human Immunology & Immunotherapy Initiative (HI³) – HI³ is working on experimental models
for the preclinical testing of therapeutics, reliable immunotherapeutic
production, consistent clinical trials research support, and organized
immune monitoring capabilities.
• RNA Bioscience Initiative –
While modern biology has been revolutionized by the discovery that many
processes of fundamental importance are regulated by RNA molecules,
major knowledge gaps remain in the basic, diagnostic and therapeutic
areas of RNA bioscience.